Regeneron Pharmaceuticals, Inc. (REGN) 10-Year Financial Performance & Capital Metrics

REGN • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AboutRegeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Show more

Revenue $14.2B +8.3%
EBITDA $4.47B -6.2%
Net Income $4.41B +11.6%
EPS (Diluted) 38.34 +10.3%
Gross Margin 86.13% +3.9%
EBITDA Margin 31.5% -13.4%
Operating Margin 28.1% -15.2%
Net Margin 31.07% +3.1%
ROE 15.95% -1.9%
ROIC 10.78% -20.3%
Debt/Equity 0.09 -11.5%
Interest Coverage 72.30 +21.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong 5Y profit CAGR of 15.8%
✓FCF machine: 25.8% free cash flow margin
✓Strong 5Y sales CAGR of 16.7%
✓Good 3Y average ROE of 17.7%
✓Healthy 5Y average net margin of 37.7%

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y17.55%

5Y16.71%

3Y-4.04%

TTM2.89%

Profit (Net Income) CAGR

10Y28.91%

5Y15.84%

3Y-18.25%

TTM-1.64%

EPS CAGR

10Y29.11%

5Y15.74%

3Y-18.93%

TTM3.34%

ROCE

10Y Avg26.2%

5Y Avg25.38%

3Y Avg16.94%

Latest12.57%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	4.1B	4.86B	5.87B	6.71B	6.56B	8.5B	16.07B	12.17B	13.12B	14.2B
Revenue Growth %	0.46%	0.18%	0.21%	0.14%	-0.02%	0.3%	0.89%	-0.24%	0.08%	0.08%
Cost of Goods Sold+	467.62M	404.44M	542.53M	582.3M	975.4M	1.36B	2.72B	1.71B	2.24B	1.97B
COGS % of Revenue	0.11%	0.08%	0.09%	0.09%	0.15%	0.16%	0.17%	0.14%	0.17%	0.14%
Gross Profit+	3.64B	4.46B	5.33B	6.13B	5.58B	7.14B	13.35B	10.47B	10.87B	12.23B
Gross Margin %	0.89%	0.92%	0.91%	0.91%	0.85%	0.84%	0.83%	0.86%	0.83%	0.86%
Gross Profit Growth %	0.42%	0.23%	0.2%	0.15%	-0.09%	0.28%	0.87%	-0.22%	0.04%	0.12%
Operating Expenses+	2.38B	3.13B	3.25B	3.59B	3.37B	3.56B	4.4B	5.08B	6.52B	8.24B
OpEx % of Revenue	0.58%	0.64%	0.55%	0.54%	0.51%	0.42%	0.27%	0.42%	0.5%	0.58%
Selling, General & Admin	838.53M	1.18B	1.32B	1.56B	1.34B	1.35B	1.82B	2.12B	2.54B	2.95B
SG&A % of Revenue	0.2%	0.24%	0.22%	0.23%	0.2%	0.16%	0.11%	0.17%	0.19%	0.21%
Research & Development	1.55B	1.95B	1.93B	2.04B	2.24B	2.5B	2.62B	3.06B	3.99B	5.23B
R&D % of Revenue	0.38%	0.4%	0.33%	0.3%	0.34%	0.29%	0.16%	0.25%	0.3%	0.37%
Other Operating Expenses	0	0	0	0	-209.2M	-280.4M	-45.6M	-89.9M	-2.1M	53.4M
Operating Income+	1.25B	1.33B	2.08B	2.53B	2.21B	3.58B	8.95B	5.39B	4.35B	3.99B
Operating Margin %	0.31%	0.27%	0.35%	0.38%	0.34%	0.42%	0.56%	0.44%	0.33%	0.28%
Operating Income Growth %	0.52%	0.06%	0.56%	0.22%	-0.13%	0.62%	1.5%	-0.4%	-0.19%	-0.08%
EBITDA+	1.33B	1.44B	2.23B	2.68B	2.42B	3.81B	9.23B	5.73B	4.77B	4.47B
EBITDA Margin %	0.32%	0.3%	0.38%	0.4%	0.37%	0.45%	0.57%	0.47%	0.36%	0.31%
EBITDA Growth %	0.51%	0.08%	0.55%	0.21%	-0.1%	0.58%	1.42%	-0.38%	-0.17%	-0.06%
D&A (Non-Cash Add-back)	74.91M	104.75M	145.47M	148.2M	210.3M	235.9M	286.2M	341.4M	421M	482.9M
EBIT	1.24B	1.34B	2.1B	2.58B	2.46B	3.87B	9.38B	4.92B	4.27B	4.84B
Net Interest Income+	-7.96M	-7.2M	-25.12M	-28.2M	-30.2M	-56.9M	-57.3M	100.7M	422.9M	656.2M
Interest Income	6.28M	0	0	0	0	0	0	160.1M	495.9M	711.4M
Interest Expense	14.24M	7.2M	25.12M	28.2M	30.2M	56.9M	57.3M	59.4M	73M	55.2M
Other Income/Expense	-26.82M	-926K	-1.08M	19.1M	219.3M	233.8M	379M	-526.8M	-149.3M	789.2M
Pretax Income+	1.23B	1.33B	2.08B	2.55B	2.43B	3.81B	9.33B	4.86B	4.2B	4.78B
Pretax Margin %	0.3%	0.27%	0.35%	0.38%	0.37%	0.45%	0.58%	0.4%	0.32%	0.34%
Income Tax+	589.04M	434.29M	880M	109.1M	313.3M	297.2M	1.25B	520.4M	245.7M	367.3M
Effective Tax Rate %	0.52%	0.67%	0.58%	0.96%	0.87%	0.92%	0.87%	0.89%	0.94%	0.92%
Net Income+	636.06M	895.52M	1.2B	2.44B	2.12B	3.51B	8.08B	4.34B	3.95B	4.41B
Net Margin %	0.15%	0.18%	0.2%	0.36%	0.32%	0.41%	0.5%	0.36%	0.3%	0.31%
Net Income Growth %	0.83%	0.41%	0.34%	1.04%	-0.13%	0.66%	1.3%	-0.46%	-0.09%	0.12%
Net Income (Continuing)	636.06M	895.52M	1.2B	2.44B	2.12B	3.51B	8.08B	4.34B	3.95B	4.41B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	5.52	7.70	10.34	21.29	18.46	30.52	71.97	38.22	34.77	38.34
EPS Growth %	0.85%	0.39%	0.34%	1.06%	-0.13%	0.65%	1.36%	-0.47%	-0.09%	0.1%
EPS (Basic)	6.17	8.55	11.27	21.29	19.38	32.65	76.40	40.51	37.05	40.90
Diluted Shares Outstanding	115.23M	116.3M	115.91M	114.8M	114.6M	115.1M	112.2M	113.5M	113.7M	115.1M
Basic Shares Outstanding	115.23M	116.25M	115.9M	114.8M	109.2M	107.6M	105.7M	107.1M	106.7M	107.9M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	3.38B	3.91B	5.6B	7.96B	7.69B	9.78B	14.01B	15.88B	19.48B	18.66B
Cash & Short-Term Investments	1.05B	1.04B	1.41B	2.81B	3.21B	3.59B	5.69B	7.74B	10.84B	9.01B
Cash Only	809.1M	535.2M	812.73M	1.47B	1.62B	2.19B	2.89B	3.11B	2.73B	2.49B
Short-Term Investments	236.12M	503.48M	596.85M	1.34B	1.6B	1.39B	2.81B	4.64B	8.11B	6.52B
Accounts Receivable	1.47B	1.61B	1.97B	2.24B	2.79B	4.11B	6.04B	5.33B	5.67B	6.21B
Days Sales Outstanding	130.55	121.03	122.72	122.01	155.05	176.75	137.09	159.78	157.7	159.65
Inventory	238.58M	399.36M	726.14M	1.15B	1.42B	1.92B	1.95B	2.4B	2.58B	3.09B
Days Inventory Outstanding	186.22	360.41	488.53	721.6	529.69	515.98	261.49	514.13	419.64	571.87
Other Current Assets	0	0	0	0	0	0	0	0	386.6M	349.2M
Total Non-Current Assets+	2.69B	3.79B	4.43B	5.29B	7.12B	7.38B	11.42B	13.33B	13.6B	19.1B
Property, Plant & Equipment	1.59B	2.08B	2.36B	2.58B	2.89B	3.22B	3.48B	3.76B	4.15B	4.6B
Fixed Asset Turnover	2.57x	2.33x	2.49x	2.61x	2.27x	2.64x	4.62x	3.23x	3.16x	3.09x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	6.7M	915.5M	1.04B	1.15B
Long-Term Investments	632.16M	864.26M	1.49B	1.75B	3.26B	3.14B	6.84B	6.59B	5.4B	8.9B
Other Non-Current Assets	5.81M	20.29M	77.9M	127.4M	144.7M	168.1M	216.1M	336.4M	444.1M	1.14B
Total Assets+	5.61B	6.97B	8.76B	11.73B	14.81B	17.16B	25.43B	29.21B	33.08B	37.76B
Asset Turnover	0.73x	0.70x	0.67x	0.57x	0.44x	0.50x	0.63x	0.42x	0.40x	0.38x
Asset Growth %	0.45%	0.24%	0.26%	0.34%	0.26%	0.16%	0.48%	0.15%	0.13%	0.14%
Total Current Liabilities+	811.16M	1.24B	1.14B	1.44B	2.1B	2.7B	3.93B	3.14B	3.42B	3.94B
Accounts Payable	140.96M	134.98M	178.2M	218.2M	418.1M	475.5M	564M	589.2M	606.6M	789.5M
Days Payables Outstanding	110.03	121.82	119.89	136.77	156.46	128.01	75.58	126.12	98.65	146.24
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	13.56M	1.18M	0	0	85M	0	0	0	0	0
Current Ratio	4.17x	3.15x	4.93x	5.52x	3.67x	3.63x	3.56x	5.06x	5.69x	4.73x
Quick Ratio	3.88x	2.83x	4.29x	4.72x	2.99x	2.91x	3.07x	4.29x	4.94x	3.95x
Cash Conversion Cycle	206.75	359.62	491.36	706.83	528.28	564.71	323	547.79	478.69	585.28
Total Non-Current Liabilities+	1.14B	1.28B	1.48B	1.53B	1.62B	3.44B	2.73B	3.41B	3.68B	4.46B
Long-Term Debt	0	0	0	0	0	1.98B	1.98B	1.98B	1.98B	1.98B
Capital Lease Obligations	362.92M	351.57M	703.5M	708.5M	713.9M	717.2M	0	720M	720M	720M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	115.53M	100.39M	949.29M	546.6M	395.3M	687.1M	680.2M	638M	854.1M	1.57B
Total Liabilities	1.95B	2.52B	2.62B	2.98B	3.72B	6.14B	6.67B	6.55B	7.11B	8.41B
Total Debt+	375.51M	481.13M	703.45M	708.5M	713.9M	2.7B	2.7B	2.7B	2.7B	2.7B
Net Debt	-433.59M	-54.08M	-109.28M	-759.2M	-903.9M	502M	-185.9M	-404.5M	-27.1M	216.2M
Debt / Equity	0.10x	0.11x	0.11x	0.08x	0.06x	0.24x	0.14x	0.12x	0.10x	0.09x
Debt / EBITDA	0.28x	0.34x	0.32x	0.26x	0.29x	0.71x	0.29x	0.47x	0.57x	0.60x
Net Debt / EBITDA	-0.33x	-0.04x	-0.05x	-0.28x	-0.37x	0.13x	-0.02x	-0.07x	-0.01x	0.05x
Interest Coverage	87.91x	184.95x	82.79x	89.87x	73.17x	62.86x	156.14x	90.67x	59.57x	72.30x
Total Equity+	3.65B	4.45B	6.14B	8.76B	11.09B	11.03B	18.77B	22.66B	25.97B	29.35B
Equity Growth %	0.44%	0.22%	0.38%	0.43%	0.27%	-0.01%	0.7%	0.21%	0.15%	0.13%
Book Value per Share	31.72	38.26	53.01	76.28	96.77	95.79	167.28	199.68	228.44	255.03
Total Shareholders' Equity	3.65B	4.45B	6.14B	8.76B	11.09B	11.03B	18.77B	22.66B	25.97B	29.35B
Common Stock	108K	110K	112K	100K	100K	100K	100K	100K	100K	100K
Retained Earnings	852.7M	1.75B	2.95B	5.25B	7.38B	10.89B	18.97B	23.31B	27.26B	31.67B
Treasury Stock	-306.07M	-316.24M	-316.24M	-396.4M	-739.9M	-6.61B	-8.26B	-10.35B	-12.56B	-15.17B
Accumulated OCI	8.57M	-12.84M	640K	-12.3M	21.1M	29.3M	-26.2M	-238.8M	-80.9M	-7.9M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	1.33B	1.49B	1.31B	2.2B	2.43B	2.62B	7.08B	5.01B	4.59B	4.42B
Operating CF Margin %	0.32%	0.31%	0.22%	0.33%	0.37%	0.31%	0.44%	0.41%	0.35%	0.31%
Operating CF Growth %	0.77%	0.12%	-0.12%	0.68%	0.11%	0.08%	1.7%	-0.29%	-0.08%	-0.04%
Net Income	636.06M	895.52M	1.2B	2.44B	2.12B	3.51B	8.08B	4.34B	3.95B	4.41B
Depreciation & Amortization	74.91M	104.75M	145.47M	148.2M	210.3M	235.9M	286.2M	341.4M	421M	482.9M
Stock-Based Compensation	459.05M	559.88M	507.28M	427.4M	464.3M	432M	601.7M	725M	885M	982.8M
Deferred Taxes	-121.62M	-360.08M	318.81M	-140M	-130.6M	75.6M	-147.1M	-746.4M	-837.8M	-757.3M
Other Non-Cash Items	52.56M	57.64M	63.57M	12.1M	-29.3M	-135M	181.7M	599.8M	266.3M	-82.2M
Working Capital Changes	229.83M	228.19M	-926.53M	-697M	-200.5M	-1.5B	-1.92B	-243.3M	-94.1M	-618.3M
Change in Receivables	-491.42M	-143.83M	-362.72M	-268.9M	-473.1M	-1.36B	-1.93B	707.8M	-338.8M	-554M
Change in Inventory	-111.83M	-149.78M	-314.19M	-387.9M	-335.5M	-529.4M	-494.3M	-696.5M	-271.7M	-619.7M
Change in Payables	303.66M	253.98M	-23.19M	210M	444.5M	118.9M	866.1M	-138.4M	598.6M	735.1M
Cash from Investing+	-907.6M	-1.05B	-1.01B	-1.46B	-2.03B	-70.6M	-5.38B	-3.78B	-3.19B	-2.47B
Capital Expenditures	-677.93M	-511.9M	-272.6M	-383.1M	-429.6M	-614.6M	-551.9M	-590.1M	-926.4M	-755.9M
CapEx % of Revenue	0.17%	0.11%	0.05%	0.06%	0.07%	0.07%	0.03%	0.05%	0.07%	0.05%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-41K	-26K	-1.08B	-429.6M	-614.6M	-551.9M	-1.03B	0	-105.6M
Cash from Financing+	-262.8M	-700.39M	-24.4M	-77.1M	-252.1M	-1.97B	-1.01B	-1.01B	-1.79B	-2.2B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-168.17M	-516.59M	0	-187.2M	-188M	2.58B	-1.03B	-445.7M	0	-33.4M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	652.85M	974M	1.03B	1.81B	2B	2B	6.53B	4.42B	3.67B	3.66B
FCF Margin %	0.16%	0.2%	0.18%	0.27%	0.31%	0.24%	0.41%	0.36%	0.28%	0.26%
FCF Growth %	0.56%	0.49%	0.06%	0.75%	0.1%	0%	2.26%	-0.32%	-0.17%	-0%
FCF per Share	5.67	8.37	8.93	15.78	17.46	17.41	58.19	38.99	32.26	31.84
FCF Conversion (FCF/Net Income)	2.09x	1.66x	1.09x	0.90x	1.15x	0.75x	0.88x	1.16x	1.16x	1.00x
Interest Paid	10.58M	5.5M	18.7M	22.3M	25M	23.2M	55.8M	53.7M	73.1M	52.6M
Taxes Paid	276.09M	481.4M	754.8M	205.6M	342.3M	188.1M	1.22B	1.5B	870.3M	743M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	20.53%	22.1%	22.63%	32.81%	21.32%	31.77%	54.21%	20.94%	16.26%	15.95%
Return on Invested Capital (ROIC)	33.69%	26.21%	29.91%	27.09%	18.23%	24.71%	44.57%	19.78%	13.53%	10.78%
Gross Margin	88.61%	91.68%	90.76%	91.32%	85.13%	84.04%	83.05%	85.99%	82.89%	86.13%
Net Margin	15.5%	18.42%	20.41%	36.42%	32.26%	41.35%	50.25%	35.64%	30.14%	31.07%
Debt / Equity	0.10x	0.11x	0.11x	0.08x	0.06x	0.24x	0.14x	0.12x	0.10x	0.09x
Interest Coverage	87.91x	184.95x	82.79x	89.87x	73.17x	62.86x	156.14x	90.67x	59.57x	72.30x
FCF Conversion	2.09x	1.66x	1.09x	0.90x	1.15x	0.75x	0.88x	1.16x	1.16x	1.00x
Revenue Growth	45.55%	18.44%	20.82%	14.28%	-2.28%	29.58%	89.14%	-24.26%	7.76%	8.27%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	4.11B	4.83B	5.57B	12.12B	6.89B	7.08B	7.63B
Product Growth	-	-	-	-	17.73%	15.17%	117.64%	-43.11%	2.67%	7.79%
Collaboration Revenue	-	-	-	-	-	-	-	2.06B	5.5B	6.06B
Collaboration Revenue Growth	-	-	-	-	-	-	-	-	167.35%	10.08%
Product and Service, Other	-	-	-	-	-	-	281.2M	365.1M	536.1M	515M
Product and Service, Other Growth	-	-	-	-	-	-	-	29.84%	46.84%	-3.94%
Antibody Collaboration	662.99M	440.17M	553.69M	-	-	-	-	-	-	-
Antibody Collaboration Growth	-	-33.61%	25.79%	-	-	-	-	-	-	-
Immuno-oncology Agreement	79.96M	218.5M	323.5M	-	-	-	-	-	-	-
Immuno-oncology Agreement Growth	-	173.25%	48.06%	-	-	-	-	-	-	-
Aflibercept Agreement	15.92M	26.2M	24.8M	-	-	-	-	-	-	-
Aflibercept Agreement Growth	-	64.55%	-5.34%	-	-	-	-	-	-	-
IO Agreement	640M	640M	-	-	-	-	-	-	-	-
IO Agreement Growth	-	0.00%	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Regeneron Pharmaceuticals, Inc. (REGN) has a price-to-earnings (P/E) ratio of 19.4x. This is roughly in line with market averages.

Growth & Financials

Regeneron Pharmaceuticals, Inc. (REGN) reported $14.25B in revenue for fiscal year 2024. This represents a 3096% increase from $445.8M in 2011.

Regeneron Pharmaceuticals, Inc. (REGN) grew revenue by 8.3% over the past year. This is steady growth.

Yes, Regeneron Pharmaceuticals, Inc. (REGN) is profitable, generating $4.58B in net income for fiscal year 2024 (31.1% net margin).

Dividend & Returns

Regeneron Pharmaceuticals, Inc. (REGN) has a return on equity (ROE) of 16.0%. This is reasonable for most industries.

Regeneron Pharmaceuticals, Inc. (REGN) generated $4.15B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...